Aiforia Technologies plc (HEL:AIFORIA), a provider of AI-assisted medical software solutions, on Friday introduced a new CE-IVD marked clinical AI solution designed to detect and quantify lymph node metastases in breast cancer, melanoma and colorectal cancer.

The model was developed in collaboration with the University of Bern.

Lymph node screening is a labour-intensive step in cancer staging, often requiring pathologists to examine multiple slides under time pressure. Aiforia's AI tool accelerates this process by guiding users to relevant regions within the slides, enabling workflow efficiency gains of up to 40%.

Chief executive Jukka Tapaninen said the new offering supports greater consistency in diagnostics while helping pathologists reduce the risk of missed metastases.